1 / 16

Evaluation Issues: NH Multi-Payer Medical Home Pilot

This evaluation aims to determine the value created by patient-centered medical homes in terms of cost savings and higher quality of care. It will also assess the correlation between different metrics and value creation. Additionally, the evaluation will explore the dose-response relationship and identify specific elements of the medical home model that have better outcomes.

seibert
Download Presentation

Evaluation Issues: NH Multi-Payer Medical Home Pilot

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Evaluation Issues:NH Multi-Payer Medical Home Pilot October 28, 2008

  2. Major Evaluation Questions • If payers and providers make the investment in patient-centered medical homes, can it create value (as defined by cost savings or higher quality of care)? • Will there be sufficient value created to cover costs of investment? • What are the metrics that are best correlated to value creation?

  3. Possible Secondary Evaluation Questions • Is there a dose-response (better outcomes with higher levels of Medical Home) • Are there specific elements of PCMH that are better correlated with outcomes • How did practices transform

  4. Methods Overview • Qualitative and descriptive. Best suited for process improvement, and sharing lessons learned regarding infrastructure issues, support teams etc… • Quantitative. Quasi-experimental design involving simple pre-post comparisons, contemporaneous controls and interrupted time series. Metrics include: cost, quality (structural efficiency measures and process), patient experience, and provider satisfaction.

  5. What Cost Outcomes? Prior consensus: • Standard utilization metrics • Avoidable in-patient stays • ED utilization • Office visits (specialty, primary care) • Pharmacy • Outpatient procedures and diagnostics • Total cost • Risk adjustment • CHIS data and software available

  6. Which Quality Outcomes Measures? Recommend: • CMS Group Practice Demo Metrics • Clinical outcomes consistent with other pilots

  7. Claims Based Hgb-A1c tests LDL test Microalbumin testing or Dx/Tx for nephropathy Retinal exam by MD/OD: 1year/high risk, 2 years/low risk Chart/Hybrid Based HgbA1c ≤ 9.0% BP< 140/90 LDL<130 Complete foot exam documented Influenza vaccine Pneumoccocal vaccine Quality Measures: Diabetes% of patients in performance year with

  8. Claims Based Lipid profile Chart/Hybrid Based LDL<130 Antiplatelet Rx Lipid Rx Hx MI, on ß-blockers BP @ last visit DM &/or LVSD on ACEI Quality Measures: CAD% of patients in performance year with

  9. Claims Based LV-EF in same year if hospitalized for HF Chart/Hybrid Based Qualitative/quantitative LVF Assessment Visits Weight documented Visits BP documented HF Education documented in last 6 months LVSD on ß-blocker LVSD on ACEI HF/AF on Warfarin Influenza vaccine Pneumococcal vaccine Quality Measures: HF% of patients in performance year with

  10. Claims Based ♀ 50-69 y.o. w/ mammogram in current or prior year Chart/Hybrid Based “Screened” for colon Cancer BP documented Last BP<140/90 If BP is >140/>90  documented plan of care Quality Measures: Preventive Care% of patients in performance year with

  11. Which P4P Measures? Recommend PQRI Measures : (up to 4% Medicare payment) • Electronic prescribing • Chronic care management • Diabetes: HgbA1c Control, LDL Control, BP Control, Dilated Eye Exam, Urine Microalbumin • CHF: ACEI/ARB, betablocker • Asthma: pharmacologic therapy • CAD: antiplatelet therapy, betablocker post MI, ASA post MI • Care coordination: Medication reconciliation • Prevention • Flu vaccine • Pneumovax

  12. Outcomes: Infrastructure • Assessing Level of Medical Home • Pre-post design • Validation of practice transformation • Determination of what makes a difference • Correlation issues • Instruments: • NCQA (a priori, therefore predictor not an outcome) • Medical Home Index • TransforMed • Starfield survey • Primary Care Assessment Survey (PCAS)

  13. Which Infrastructure Tools? Recommend: • Medical Home Index • Starfield survey • Primary Care Assessment Survey (PCAS) • TransforMed

  14. Other Domains Recommend: • Patient perspective: • PCAS (based on CG-CAHPS) • Practice culture, teamwork, staff satisfaction: • Assessing the culture of Medial Group Practice (Krelewski) • Practice staff Questionnaire (PSQ) (Stange, Crabtree, et al) • Microsystems Assessment Tool (Nutting) • Leadership capacity (MHIQ subsection) • Community Linkages section of Assessing Chronic Illness survey (Wagner)

  15. Unresolved Analytic Issues • Sample size and power calculations • How many comparisons can we make? • Unit of analysis • Practices vs Practitioners • Individual patients vs Patient panels • Will P4P confound outcomes measurement and does it matter

  16. Next Steps Recommend: • Select principal investigator • David Laflamme, UNH ? • Andy Coburn, Muskie ? • PCMH evaluation consultation • Meredith Rosenthal, HSPH • PI writes evaluation plan before start of pilot • Evaluation plan agreed upon by practices • PI and workgroup seeks evaluation funding • Consider collaboration with Maine (RWJF)

More Related